NCT06736223View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function

PHASE1RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Hepatic Impairment

Interventions

DRUG

ITF2357

ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose

Trial Locations (3)

1606

RECRUITING

MC COMAC Medical Ltd, Sofia

1612

RECRUITING

MC COMAC Medical Ltd, Sofia

35042

NOT_YET_RECRUITING

Biotrial, Rennes

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Biotrial

INDUSTRY

lead

Italfarmaco

INDUSTRY